SNDX241220C5000
- 0.00
- 0.000.00%
Syndax Pharmaceuticals Newsroom
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $42 to $51
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $25 to $51
Syndax Pharmaceuticals (SNDX) Receives a Buy From Stifel Nicolaus
Syndax Pharmaceuticals (SNDX) Gets a Buy From TD Cowen
Syndax Pharmaceuticals Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Syndax Pharmaceuticals Analyst Ratings
Edward White Issues Buy Rating for Syndax Pharmaceuticals Due to Promising Revuforj Data and Market Potential
Barclays Releases a Buy Rating on Syndax Pharmaceuticals (SNDX)
Analysts Conflicted on These Healthcare Names: Revance Therapeutics (RVNC), Syndax Pharmaceuticals (SNDX) and Align Tech (ALGN)
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), UnitedHealth (UNH) and Disc Medicine (IRON)
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $25
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $25
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $38
Syndax Pharmaceuticals Is Maintained at Buy by Citigroup
Syndax Pharmaceuticals Analyst Ratings
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Maintains Target Price $18
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $33 to $51
Syndax Pharmaceuticals (SNDX) Gets a Buy From Barclays
Syndax Pharmaceuticals' Promising Outlook: Revumenib Approval and Market Potential Justify Buy Rating
Syndax Pharmaceuticals (SNDX) Gets a Buy From TD Cowen